A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Clinical trial NCT00777036 · COMPLETED

Trial details

NCT number

NCT00777036

Sponsor

Bristol-Myers Squibb

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2009-03-20

Primary completion

2016-09-01

Enrollment

133

View on ClinicalTrials.gov